Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

NAO.VNS: A New Personalized Neural Stimulation Therapy For Drug-resistant Epilepsy

Obiettivo

19.5M world population suffer from Drug-Resistant Epilepsy (DRE) with symptoms poorly controlled. 8M are not eligible for brain surgery. Vagus nerve stimulation is nowadays the best treatment option. But unfortunately, current solutions do not reply to the clinical need. They cannot adapt to each patient making the patient's therapeutic journey complicated and expensive.

We created NAO.VNS the next-generation implantable vagus nerve neurostimulator. We replaced metal wires by optical fibres to convert optical energy to electrical impulses rendering the device compliant with MRI & brain scans essential for disease diagnosis or treatment. Through NAO.VNS patients & physicians receive remote feedback on the direct effect & efficacy of the neural stimulation, to precisely & uniquely adapt therapy.

Through EIC funding, we will complete a clinical pilot trial & a pivotal study in the EU/US to initiate market approvals. We expect to generate €89M by 2028 selling in the EU/US.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-EIC-2022-ACCELERATOR-01

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

SYNERGIA MEDICAL
Contributo netto dell'UE
€ 2 499 000,00
Indirizzo
RUE EMILE FRANCQUI 6
1435 Mont-Saint-Guibert
Belgio
PMI
Sì
Regione
Région wallonne Prov. Brabant Wallon Arr. Nivelles
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
€ 4 471 250,00